Role of the inflammatory response in community-acquired pneumonia: clinical implications.
Alexander RombautsGabriela Abelenda-AlonsoGuillermo CuervoCarlota GudiolJordi CarratalaPublished in: Expert review of anti-infective therapy (2021)
Notable efforts have been made to identify biomarkers that can accurately differentiate between viral and bacterial etiology, and indeed, to enhance risk stratification in CAP. However, none has proven ideal and no recommended biomarker-guided algorithms exist. Biomarker signatures from proteomic and metabolomic studies could be more useful for such assessments. To date, most studies have produced contradictory results concerning the role of immunomodulatory agents (e.g. corticosteroids, macrolides, and statins) in CAP. Adequately identifying the population who may benefit most from effective modulation of the inflammatory response remains a challenge.